• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊沙佐米成功治疗由骨髓增生异常综合征转化而来的复发难治性急性髓系白血病。

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.

作者信息

Oka Satoko, Ono Kazuo

机构信息

Division of Hematology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

Division of Pathology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

出版信息

Clin Case Rep. 2021 Jun 23;9(6):e04287. doi: 10.1002/ccr3.4287. eCollection 2021 Jun.

DOI:10.1002/ccr3.4287
PMID:34194792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8222761/
Abstract

Elevated NF-kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF-kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.

摘要

在骨髓增生异常综合征/急性髓系白血病（MDS/AML）患者的原始骨髓细胞中已发现核因子-κB（NF-κB）水平升高，这表明NF-κB是MDS/AML的一个治疗靶点。我们在此描述了一名不符合造血干细胞移植（SCT）条件的MDS患者，该患者在接受阿扎胞苷和硼替佐米治疗后转变为白血病，但在接受伊沙佐米单药治疗后维持完全缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e3/8222761/e08bb0be600a/CCR3-9-e04287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e3/8222761/e08bb0be600a/CCR3-9-e04287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e3/8222761/e08bb0be600a/CCR3-9-e04287-g001.jpg

相似文献

1
Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.伊沙佐米成功治疗由骨髓增生异常综合征转化而来的复发难治性急性髓系白血病。
Clin Case Rep. 2021 Jun 23;9(6):e04287. doi: 10.1002/ccr3.4287. eCollection 2021 Jun.
2
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.每日两次氟达拉滨和阿糖胞苷联合或不联合吉妥珠单抗奥佐米星对复发/难治性急性髓系白血病、高危骨髓增生异常综合征和急变期慢性髓系白血病患者有效。
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.
3
[High Risk Factors for Transformation into Acute myeloid Leukemia in Patients with Intermediate and High Risk Myelodysplastic syndrome].[中高危骨髓增生异常综合征患者转化为急性髓系白血病的高危因素]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):558-566. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.034.
4
Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.骨髓增生异常综合征、骨髓增生异常综合征衍生的急性髓系白血病和原发性急性髓系白血病中的细胞凋亡、bcl-2表达及p53蓄积
Acta Haematol. 2000;102(3):115-23. doi: 10.1159/000040984.
5
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.真实世界中阿扎胞苷治疗骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病的疗效和安全性数据。
Pathol Oncol Res. 2019 Jul;25(3):1175-1180. doi: 10.1007/s12253-018-00574-0. Epub 2019 Jan 6.
6
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.伊达比星、阿糖胞苷和拓扑替康用于难治性或复发性急性髓性白血病及高危骨髓增生异常综合征患者。
Am J Hematol. 2001 Dec;68(4):237-45. doi: 10.1002/ajh.1188.
7
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.急性髓系白血病和骨髓增生异常综合征患者骨髓中神经纤维瘤病1蛋白水平及ras癌基因突变的预后意义
Cancer. 2003 Jan 15;97(2):441-9. doi: 10.1002/cncr.11036.
8
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.一项硼替佐米联合每周伊达比星治疗老年急性髓系白血病的 I 期研究。
Leuk Res. 2013 Nov;37(11):1502-8. doi: 10.1016/j.leukres.2013.09.003. Epub 2013 Sep 8.
9
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.外周血 CD34 供者嵌合状态比 CD3 更具临床实用性，可用于检测急性髓系白血病或骨髓增生异常综合征患者异基因造血干细胞移植后复发。
Transplant Cell Ther. 2023 Jul;29(7):454.e1-454.e8. doi: 10.1016/j.jtct.2023.03.025. Epub 2023 Mar 24.
10
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome.核因子-κB是高危骨髓增生异常综合征的一个潜在治疗靶点。
Blood. 2006 Feb 1;107(3):1156-65. doi: 10.1182/blood-2005-05-1989. Epub 2005 Oct 13.

引用本文的文献

1
Bortezomib Eliminates Persistent Infection through Rapid and Specific Host Cell Apoptosis.硼替佐米通过快速和特异性宿主细胞凋亡消除持续性感染。
Int J Mol Sci. 2022 Jul 4;23(13):7434. doi: 10.3390/ijms23137434.

本文引用的文献

1
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.一项在复发/难治性急性髓系白血病患者中联合使用 MEC（米托蒽醌、依托泊苷、阿糖胞苷）和伊沙佐米的 I/II 期临床试验。
Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.
2
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.硼替佐米对低危骨髓增生异常综合征患者的探索性临床试验。
Am J Hematol. 2017 Jul;92(7):674-682. doi: 10.1002/ajh.24746. Epub 2017 Jun 9.
3
The role of the proteasome in AML.
蛋白酶体在急性髓系白血病中的作用。
Blood Cancer J. 2016 Dec 2;6(12):e503. doi: 10.1038/bcj.2016.112.
4
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).来那度胺治疗的伴有孤立性5号染色体长臂缺失（5q-）的骨髓增生异常综合征患者中TP53突变的患病率、克隆动力学及临床影响：德国骨髓增生异常综合征研究组（GMDS）一项前瞻性多中心研究的结果
Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2.
5
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.表达突变细胞质 NPM1 的人白血病细胞中研究性 ixazomib 的选择性毒性：活性氧的作用。
Clin Cancer Res. 2016 Apr 15;22(8):1978-88. doi: 10.1158/1078-0432.CCR-15-1440. Epub 2015 Dec 3.
6
Update on proteasome inhibitors in multiple myeloma.多发性骨髓瘤中蛋白酶体抑制剂的最新进展
Clin Adv Hematol Oncol. 2014 Mar;12(3):179-81.
7
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.口服蛋白酶体抑制剂伊沙佐米每周两次用于复发/难治性多发性骨髓瘤患者的1期研究。
Blood. 2014 Aug 14;124(7):1038-46. doi: 10.1182/blood-2014-01-548826. Epub 2014 Jun 11.
8
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者每周口服试验性蛋白酶体抑制剂伊沙佐米的1期研究。
Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5.
9
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.硼替佐米联合柔红霉素和阿糖胞苷用于诱导治疗，并在初治 60-75 岁急性髓系白血病患者中联合中剂量阿糖胞苷用于巩固治疗：CALGB（Alliance）研究 10502。
J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.
10
Proteasome inhibitors in multiple myeloma: 10 years later.蛋白酶体抑制剂在多发性骨髓瘤中的应用：10 年进展。
Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29.